Kerrisdale Capital Issues Positive Report on Adamas Pharmaceuticals, Inc., and Announces Conference Call Schedule

NEW YORK, Nov. 1, 2017 /PRNewswire/ -- Kerrisdale Capital, a private investment manager, has published a report explaining its long position in Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS), a ~$500 million company that develops treatments for chronic neurological disorders. Kerrisdale believes that Adamas's drug Gocovri, which is set to hit the market next year, will reach blockbuster status, bringing the fair value of Adamas to more than $100 per share – more than 4x higher than its current price. While critics dismiss Gocovri as a me-too drug, trial data shows that it in fact greatly improves on existing treatments.

The full report can be found at http://kerr.co/adms.

Kerrisdale has a long position in Adamas Pharmaceuticals and stands to benefit if its share price rises.

Conference Call Schedule
Kerrisdale will host a conference call on Wednesday, November 1 at 10:30am ET to discuss the Adamas Pharmaceuticals report.

To participate in the conference call, dial 888-567-1602 (US and Canada) or 404-267-0373 (international) and reference the Kerrisdale Capital call.

About Kerrisdale Capital
Kerrisdale Capital Management, LLC, is a fundamentally-oriented investment manager that focuses on long-term value investments and event-driven special situations.

Kerrisdale Capital Management, LLC is a member of the Financial Industry Regulatory Authority, CRD number 160804.

Contact
Agnes Cao
Kerrisdale Capital
[email protected] 
212-257-4385

SOURCE Kerrisdale Capital